[Pharmacogenetics and pharmacogenomics of methotrexate. Current status and novel aspects].

Abstract excerpt

Since its introduction as a disease-modifying drug, methotrexate (MTX), a folate antagonist, is regarded as a major pillar of anti-rheumatic pharmacotherapy. This has not been changed in the current era of biologicals based on recombinant proteins. Despite most promising therapeutic progress about half of rheumatoid arthritis patients still display insufficient response to anti-rheumatic drugs. Specifically,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antirheumatic Agents
• Share to Arthritis, Rheumatoid
• Share to Genetic Predisposition to Disease